Dr. Funda Suer Joins Orchid as Executive Vice President
Orchid, a leader in reproductive technology, is excited to announce that Dr. Funda Suer has been appointed as the new Executive Vice President and Lab Medical Director. With her vast experience in genetic diagnostics and reproductive health, Dr. Suer is set to significantly contribute to the laboratory's mission of supporting couples in achieving healthier pregnancies and babies.
Advancing Reproductive Genetic Testing
Dr. Suer has built a remarkable career focused on enhancing reproductive outcomes through innovative research and clinical diagnostics. Her leadership will further strengthen Orchid's dedication to providing accurate and compassionate genetic testing services, which are essential for families looking to grow.
A Vision for Healthier Generations
Sharing her enthusiasm, Dr. Suer remarked, "I am incredibly excited to join Orchid and contribute to our shared vision of ensuring healthier babies for families. I look forward to collaborating with our talented team to make a meaningful difference in the lives of couples and their future generations." This statement highlights the increasing significance of genetic testing as families seek informed choices for their children's health.
What Makes Orchid Unique
Orchid is at the forefront of reproductive genetic testing, offering the only commercially available whole genome embryo screening in the world. By analyzing over 99% of an embryo's genome, Orchid provides a wealth of data compared to traditional methods that typically examine only a small portion. With more than 30 genome sequencing reports, Orchid demonstrates its capability to identify various genetic conditions that may impact embryo viability.
Empowering Patients with Comprehensive Data
Dr. Suer plans to elevate the laboratory's services by incorporating the latest advancements in genetic science and technology, enhancing data accuracy, and broadening testing options. This commitment ensures that every patient receives thorough support throughout their reproductive journey.
Leadership's Confidence in the Future
Noor Siddiqui, the CEO and Founder of Orchid, expressed his excitement about Dr. Suer's arrival, stating, "With her expertise and visionary approach, we are confident that Orchid will continue to lead the way in preimplantation genetic testing and make a profound impact on the lives of the families we serve." This leadership reflects a focused mission to assist more families in navigating their reproductive challenges.
About Orchid
Orchid is committed to extending the healthspan of future generations by providing prospective parents with a deeper understanding of their future child's genetic health. The organization emphasizes empowering families to make informed decisions regarding reproductive health and prenatal care.
Frequently Asked Questions
What is the significance of Dr. Funda Suer's appointment?
Dr. Funda Suer's role as Executive VP at Orchid brings a wealth of expertise in genetics, which enhances the company's commitment to reproductive health and genetic testing.
How does Orchid's testing differ from traditional methods?
Orchid's whole genome embryo testing examines over 99% of an embryo's genome, compared to the industry standard of 0.25%, allowing for a more thorough risk assessment.
What is the mission of Orchid?
Orchid aims to assist couples in achieving healthier pregnancies through innovative reproductive genetic testing technology and comprehensive insights into genetic health.
How can patients benefit from Orchid's services?
Patients receive proactive support and improved data accuracy in their genetic testing processes, which helps them better understand reproductive health risks.
Where can Orchid's services be accessed?
Orchid’s whole genome embryo reports are available at IVF centers nationwide, offering extensive testing capabilities to families across the country.
